1. Go AS, Hylek EM, Phillips KA, et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA.
2001; 285(18):2370-2375.
2. Miyasaka Y, BarnesME, Gersh BJ, et al. Secular trends in incidence of atrial fibrillation in Olmsted County, Minnesota, 1980 to 2000, and implications on the projections for future prevalence. Circulation. 2006; 114(2):119-125.
3. Benjamin EJ,Wolf PA, D’Agostino RB, Silbershatz H, Kannel WB, Levy D. Impact of atrial fibrillation on the risk of death: the Framingham Heart Study. Circulation. 1998; 98(10):946-952.
4. Miyasaka Y, BarnesME, Bailey KR, et al. Mortality trends in patients diagnosed with first atrial fibrillation: a 21-year community-based study. J AmColl Cardiol. 2007; 49(9):986-992.
5. Conen D, Chae CU, Glynn RJ, et al. Risk of death and cardiovascular events in initially healthy women with new-onset atrial fibrillation. JAMA. 2011; 305(20):2080-2087.
6. Kannel WB, Benjamin EJ. Status of the epidemiology of atrial fibrillation. Med Clin North Am. 2008; 92(1):17-40.
7. Benjamin EJ, Chen PS, Bild DE, et al. Prevention of atrial fibrillation: report from a national heart, lung, and blood institute workshop. Circulation. 2009; 119(4):606-618.
8. Schmitt J, Duray G, Gersh BJ, Hohnloser SH. Atrial fibrillation in acute myocardial infarction: a systematic review of the incidence, clinical features and prognostic implications. Eur Heart J. 2009; 30(9):1038-1045.
9. Garg RK, Jolly N. Acute myocardial infarction secondary to thromboembolism in a patient with atrial fibrillation. Int J Cardiol. 2007; 123(1):e18-e20.
10. Van deWalle S, Dujardin K. A case of coronary embolism in a patient with paroxysmal atrial fibrillation receiving tamoxifen. Int J Cardiol. 2007; 123(1):66-68.
11. Sakai K, Inoue K, Nobuyoshi M. Aspiration thrombectomy of a massive thrombotic embolus in acute myocardial infarction caused by coronary embolism. Int Heart J. 2007; 48(3):387-392.
12. Kleczyński P, Dziewierz A, Rakowski T, et al. Cardioembolic acute myocardial infarction and stroke in a patient with persistent atrial fibrillation. Int J Cardiol. 2012; 161(3):e46-e47.
13. Hernández F, Pombo M, Dalmau R, et al. Acute coronary embolism: angiographic diagnosis and treatment with primary angioplasty. Catheter Cardiovasc Interv. 2002; 55(4):491-494.
14. Iwama T, Asami K, Kubo I, Kitazume H. Hypertrophic cardiomyopathy complicated with acutemyocardial infarction due to coronary embolism. Intern Med. 1997; 36(9):613-617.
15. Takenaka T, HorimotoM, Igarashi K, Yoshie H, Tsujino I, MorihiraM. Multiple coronary thromboemboli complicating valvular heart disease and atrial fibrillation. Am Heart J. 1996; 131(1): 194-196.
16. Camaro C, Aengevaeren WR. Acute myocardial infarction due to coronary artery embolism in a patient with atrial fibrillation. Neth Heart J. 2009; 17(7-8):297-299.
17. Howard VJ, Cushman M, Pulley L, et al. The reasons for geographic and racial differences in stroke study: objectives and design. Neuroepidemiology. 2005; 25(3):135-143.
18. Safford MM, Brown TM, Muntner PM, et al; REGARDS Investigators. Association of race and sex with risk of incident acute coronary heart disease events. JAMA. 2012; 308(17):1768-1774.
19. Prineas RJ, Crow RS, Blackburn H. The Minnesota Code Manual of Electrocardiographic Findings: Standards and Procedures for Measurement and Classification. Boston, MA: Wright-OSG; 1982.
20. Soliman EZ, Howard G, Meschia JF, et al. Self-reported atrial fibrillation and risk of stroke in the Reasons for Geographic and Racial Differences in Stroke (REGARDS) study. Stroke. 2011; 42(10):2950-2953.
21. Pullicino PM, McClure LA,Wadley VG, et al. Blood pressure and stroke in heart failure in the REasons for Geographic And Racial Differences in Stroke (REGARDS) study. Stroke. 2009; 40(12): 3706-3710.
22. Gage BF,Waterman AD, ShannonW, Boechler M, RichMW, RadfordMJ. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA. 2001; 285(22):2864-2870.
23. Levey AS, Stevens LA, Schmid CH, et al; CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration). A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009; 150(9):604-612.
24. Meschia JF, Merrill P, Soliman EZ, et al. Racial disparities in awareness and treatment of atrial fibrillation: the REasons for Geographic and Racial Differences in Stroke (REGARDS) study. Stroke. 2010; 41(4):581-587.
25. Rothberg MB, Celestin C, Fiore LD, Lawler E, Cook JR.Warfarin plus aspirin after myocardial infarction or the acute coronary syndrome: meta-analysis with estimates of risk and benefit. Ann Intern Med. 2005; 143(4):241-250.
26. Lip GY, Lane DA. Does warfarin for stroke thromboprophylaxis protect against MI in atrial fibrillation patients? Am J Med. 2010; 123(9): 785-789.
27. Watanabe H,Watanabe T, Sasaki S, Nagai K, Roden DM, Aizawa Y. Close bidirectional relationship between chronic kidney disease and atrial fibrillation: the Niigata preventive medicine study. Am Heart J. 2009; 158(4):629-636.
28. Bansal N, Fan D, Hsu CY, Ordonez JD, Marcus GM, Go AS. Incident atrial fibrillation and risk of end-stage renal disease in adults with chronic kidney disease. Circulation. 2013; 127(5):569-574.
29. Wang TJ, Larson MG, Levy D, et al. Temporal relations of atrial fibrillation and congestive heart failure and their joint influence on mortality: the Framingham Heart Study. Circulation. 2003; 107(23):2920-2925.
30. Aviles RJ, Martin DO, Apperson-Hansen C, et al. Inflammation as a risk factor for atrial fibrillation. Circulation. 2003; 108(24):3006-3010.
31. Ridker PM, Rifai N, Stampfer MJ, Hennekens CH. Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men. Circulation. 2000; 101(15):1767-1772.
32. Ridker PM, Hennekens CH, Buring JE, Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med. 2000; 342(12): 836-843.
33. RienstraM, Sun JX, Magnani JW, et al. White blood cell count and risk of incident atrial fibrillation (from the Framingham Heart Study). Am J Cardiol. 2012; 109(4):533-537.
34. Issac TT, Dokainish H, Lakkis NM. Role of inflammation in initiation and perpetuation of atrial fibrillation: a systematic review of the published data. J AmColl Cardiol. 2007; 50(21):2021-2028.
35. Guo Y, Lip GY, Apostolakis S. Inflammation in atrial fibrillation. J AmColl Cardiol. 2012;60(22): 2263-2270.
36. Lim HS,Willoughby SR, Schultz C, et al. Effect of atrial fibrillation on atrial thrombogenesis in humans: impact of rate and rhythm. J AmColl Cardiol. 2013; 61(8):852-860.
37. Mondillo S, Sabatini L, Agricola E, et al. Correlation between left atrial size, prothrombotic state and markers of endothelial dysfunction in patients with lone chronic nonrheumatic atrial fibrillation. Int J Cardiol. 2000; 75(2-3):227-232.
38. Lip GY, Lowe GD, Rumley A, Dunn FG. Increased markers of thrombogenesis in chronic atrial fibrillation: effects of warfarin treatment. Br Heart J. 1995; 73(6):527-533.
39. Willoughby SR, Roberts-Thomson RL, Lim HS, et al. Atrial platelet reactivity in patients with atrial fibrillation. Heart Rhythm. 2010; 7(9):1178-1183.
40. Freedman JE, Loscalzo J. Platelet-monocyte aggregates: bridging thrombosis and inflammation. Circulation. 2002; 105(18):2130-2132.
41. Akar JG, JeskeW,Wilber DJ. Acute onset human atrial fibrillation is associated with local cardiac platelet activation and endothelial dysfunction. J AmColl Cardiol. 2008; 51(18):1790- 1793.
42. Watson T, Shantsila E, Lip GY. Mechanisms of thrombogenesis in atrial fibrillation: Virchow’s triad revisited. Lancet. 2009; 373(9658):155-166.
43. Frustaci A, Chimenti C, Bellocci F, Morgante E, Russo MA, Maseri A. Histological substrate of atrial biopsies in patients with lone atrial fibrillation. Circulation. 1997; 96(4):1180-1184.
44. Fukuchi M,Watanabe J, Kumagai K, et al. Increased vonWillebrand factor in the endocardium as a local predisposing factor for thrombogenesis in overloaded human atrial appendage. J AmColl Cardiol. 2001; 37(5):1436-1442.
45. Matsue Y, Suzuki M, Abe M, et al. Endothelial dysfunction in paroxysmal atrial fibrillation as a prothrombotic state: comparison with permanent/persistent atrial fibrillation. J Atheroscler Thromb. 2011; 18(4):298-304.
46. Wong CX, Lim HS, Schultz CD, Sanders P, Worthley MI,Willoughby SR. Assessment of endothelial function in atrial fibrillation: utility of peripheral arterial tonometry. Clin Exp Pharmacol Physiol. 2012; 39(2):141-144.
47. Minamino T, Kitakaze M, Sato H, et al. Plasma levels of nitrite/nitrate and platelet cGMP levels are decreased in patients with atrial fibrillation. Arterioscler Thromb Vasc Biol. 1997; 17(11):3191-3195.
48. Skalidis EI, Zacharis EA, Tsetis DK, et al. Endothelial cell function during atrial fibrillation and after restoration of sinus rhythm. Am J Cardiol 2007; 99(9):1258-1262.
49. Prizel KR, Hutchins GM, Bulkley BH. Coronary artery embolism and myocardial infarction. Ann Intern Med. 1978; 88(2):155-161.
50. Thygesen K, Alpert JS, White HD; Joint ESC/ACCF/AHA/WHF Task Force for the Redefinition ofMyocardial Infarction. Universal definition of myocardial infarction. Eur Heart J. 2007; 28(20):2525-2538.
51. Saaby L, Poulsen TS, Hosbond S, et al. Classification of myocardial infarction: frequency and features of type 2myocardial infarction. Am J Med. 2013; 126(9):789-797.
52. Fonseca C, Oliveira AG, Mota T, et al; EPICA Investigators. Evaluation of the performance and concordance of clinical questionnaires for the diagnosis of heart failure in primary care . Eur J Heart Fail. 2004; 6(6):813-822.